A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction
Authors: K.A. Papp, S. Tyring, M. Lahfa, J. Prinz, C.E.M. Griffiths, A.M. Nakanishi, R. Zitnik, P.C.M. van de Kerkhof
Journal: British Journal of Dermatology (2005)

Journal Article A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction Get access K.A. Papp, K.A. Papp Probity Medical Research, 135 Union Street East, Waterloo, Ontario N2J 1C4, Canada *Department of Dermatology, University of Texas Health Science Center, Houston, TX, U.S.A. †Service de Dermatologie du Pr Dubertret, Hôpital Saint‐Louis, Paris, France ‡Ludwig‐Maximilians‐Universität München, Munich, Germany §Dermatology Centre, University of Manchester, Manchester, U.K. ¶Amgen Inc., Thousand Oaks, CA, U.S.A. **Universitair Medisch Centrum St Radboud, Nijmegen, the Netherlands Kim Papp. E‐mail: kapapp@probitymedical.com Search for other works by this author on: Oxford Academic Google Scholar S. Tyring, S. Tyring Probity Medical Research, 135 Union Street East, Waterloo, Ontario N2J 1C4, Canada *Department of Dermatology, University of Texas Health Science Center, Houston, TX, U.S.A. †Service de Dermatologie du Pr Dubertret, Hôpital Saint‐Louis, Paris, France ‡Ludwig‐Maximilians‐Universität München, Munich, Germany §Dermatology Centre, University of Manchester, Manchester, U.K. ¶Amgen Inc., Thousand Oaks, CA, U.S.A. **Universitair Medisch Centrum St Radboud, Nijmegen, the Netherlands Search for other works by this author on: Oxford Academic Google Scholar M. Lahfa, M. Lahfa Probity Medical Research, 135 Union Street East, Waterloo, Ontario N2J 1C4, Canada *Department of Dermatology, University of Texas Health Science Center, Houston, TX, U.S.A. †Service de Dermatologie du Pr Dubertret, Hôpital Saint‐Louis, Paris, France ‡Ludwig‐Maximilians‐Universität München, Munich, Germany §Dermatology Centre, University of Manchester, Manchester, U.K. ¶Amgen Inc., Thousand Oaks, CA, U.S.A. **Universitair Medisch Centrum St Radboud, Nijmegen, the Netherlands Search for other works by this author on: Oxford Academic Google Scholar J. Prinz, J. Prinz Probity Medical Research, 135 Union Street East, Waterloo, Ontario N2J 1C4, Canada *Department of Dermatology, University of Texas Health Science Center, Houston, TX, U.S.A. †Service de Dermatologie du Pr Dubertret, Hôpital Saint‐Louis, Paris, France ‡Ludwig‐Maximilians‐Universität München, Munich, Germany §Dermatology Centre, University of Manchester, Manchester, U.K. ¶Amgen Inc., Thousand Oaks, CA, U.S.A. **Universitair Medisch Centrum St Radboud, Nijmegen, the Netherlands Search for other works by this author on: Oxford Academic Google Scholar C.E.M. Griffiths, C.E.M. Griffiths Probity Medical Research, 135 Union Street East, Waterloo, Ontario N2J 1C4, Canada *Department of Dermatology, University of Texas Health Science Center, Houston, TX, U.S.A. †Service de Dermatologie du Pr Dubertret, Hôpital Saint‐Louis, Paris, France ‡Ludwig‐Maximilians‐Universität München, Munich, Germany §Dermatology Centre, University of Manchester, Manchester, U.K. ¶Amgen Inc., Thousand Oaks, CA, U.S.A. **Universitair Medisch Centrum St Radboud, Nijmegen, the Netherlands Search for other works by this author on: Oxford Academic Google Scholar A.M. Nakanishi, A.M. Nakanishi Probity Medical Research, 135 Union Street East, Waterloo, Ontario N2J 1C4, Canada *Department of Dermatology, University of Texas Health Science Center, Houston, TX, U.S.A. †Service de Dermatologie du Pr Dubertret, Hôpital Saint‐Louis, Paris, France ‡Ludwig‐Maximilians‐Universität München, Munich, Germany §Dermatology Centre, University of Manchester, Manchester, U.K. ¶Amgen Inc., Thousand Oaks, CA, U.S.A. **Universitair Medisch Centrum St Radboud, Nijmegen, the Netherlands Search for other works by this author on: Oxford Academic Google Scholar R. Zitnik, R. Zitnik Probity Medical Research, 135 Union Street East, Waterloo, Ontario N2J 1C4, Canada *Department of Dermatology, University of Texas Health Science Center, Houston, TX, U.S.A. †Service de Dermatologie du Pr Dubertret, Hôpital Saint‐Louis, Paris, France ‡Ludwig‐Maximilians‐Universität München, Munich, Germany §Dermatology Centre, University of Manchester, Manchester, U.K. ¶Amgen Inc., Thousand Oaks, CA, U.S.A. **Universitair Medisch Centrum St Radboud, Nijmegen, the Netherlands Search for other works by this author on: Oxford Academic Google Scholar P.C.M. Van De Kerkhof, P.C.M. Van De Kerkhof Probity Medical Research, 135 Union Street East, Waterloo, Ontario N2J 1C4, Canada *Department of Dermatology, University of Texas Health Science Center, Houston, TX, U.S.A. †Service de Dermatologie du Pr Dubertret, Hôpital Saint‐Louis, Paris, France ‡Ludwig‐Maximilians‐Universität München, Munich, Germany §Dermatology Centre, University of Manchester, Manchester, U.K. ¶Amgen Inc., Thousand Oaks, CA, U.S.A. **Universitair Medisch Centrum St Radboud, Nijmegen, the Netherlands Search for other works by this author on: Oxford Academic Google Scholar the Etanercept Psoriasis Study Group the Etanercept Psoriasis Study Group Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 152, Issue 6, 1 June 2005, Pages 1304–1312, https://doi.org/10.1111/j.1365-2133.2005.06688.x Published: 01 June 2005 Article history Accepted: 22 February 2005 Published: 01 June 2005